PLUS1
Best deals to access real time data! |
|
Real-time Level 1 for London Stock Exchange
Monthly Subscription
for only
$26.87
|
|
London Stock Exchange Level 2
Monthly Subscription
for only
$70.55
|
|
Real-time Level 1 for London Stock Exchange + FTSE
Monthly Subscription
for only
$80.63
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Glaxosmithkline | GSK | London | Ordinary Share | GB0009252882 | ORD 25P |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +22.6 | +1.61% | 1,430 | 1,435 | 1,414.2 | 1,419 | 1,407.4 | 11:35:24 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1,425.6 | 1,426 | 0.4 | 0.03% | 2 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,673 | 8,748,291 | 1,427.6124p | 124.89Mp | - | 1,236.40 - 1,724.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:55:00 | O | 104,010 | 1,428.97p | GBX |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
Glaxosmithkline Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| 70.32Bp | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | -p | 0.00% | - | - |
Glaxosmithkline News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/20/2018 | 10:15 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC Director/PDMR Shareholding |
| 4/20/2018 | 10:15 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC Director/PDMR Shareholding |
| 4/19/2018 | 02:00 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC IMPACT study shows benefits of Trelegy.. |
| 4/18/2018 | 17:00 | Business Wire | Landmark IMPACT Study Published in NEJM Shows Significant.. |
| 4/18/2018 | 07:40 | Alliance News |  GlaxoSmithKline Gets Positive Results In Trelegy Ellipta.. |
| 4/18/2018 | 05:34 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC Landmark IMPACT study to be published in.. |
| 4/18/2018 | 05:02 | UK Regulatory (RNS & others) | GlaxoSmithKline PLC IMPACT study shows benefits of Trelegy.. |
Glaxosmithkline Discussion Forums - GSK
| Date | Time | Comments | Title |
|---|---|---|---|
| 3/04/2018 | 09:40 | - | Buy anything below 36 not much down side risk. |
| 2/08/2018 | 10:04 | - | Copy of Presentation: |
| 2/07/2018 | 07:50 | - | GSK 4Q17 CC slides: |
| 10/23/2017 | 05:30 | - | https://seekingalpha.com/article/4115400-glaxosmithkline-lands-big-win-shingles- |
| 9/13/2017 | 07:32 | - | [b]Mymetics to Present New Preclinical Data on Thermostable |
| 8/11/2017 | 05:08 | - | Breakthrough in vaccine delivery will disrupt the vaccine |
| 5/01/2017 | 10:03 | - | http://www.paneuropeannetworks.com/health/dutch-biotech-leads-vaccine-h2020-proj |
| 4/20/2017 | 10:23 | - | Google/GSK started Galvani Biosciences a private company and |
| 3/08/2017 | 08:17 | - | MACIVIVA = Game Changer |
| 3/01/2017 | 10:58 | - | For 2016, it''s been all about TAF - |
Historical GSK Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 1,436.8 | 1,436.8 | 1,399.4 | 1,414.4717 | 6M | 10M | 7M | -6.8 | -0.47% |
| 1 Month | 1,331 | 1,445.4 | 1,273.8 | 1,390.2918 | 6M | 20M | 10M | 99 | 7.44% |
| 3 Months | 1,338.6 | 1,445.4 | 1,236.4 | 1,335.6153 | 4M | 20M | 9M | 91.4 | 6.83% |
| 6 Months | 1,543 | 1,544 | 1,236.4 | 1,337.4936 | 4M | 30M | 10M | -113 | -7.32% |
| 1 Year | 1,569 | 1,724.5 | 1,236.4 | 1,450.7904 | 3M | 30M | 10M | -139 | -8.86% |
| 3 Years | 1,532.5 | 1,735.5 | 1,227.5 | 1,470.5213 | 736k | 34M | 9M | -102.5 | -6.69% |
| 5 Years | 1,673.5 | 1,816 | 1,227.5 | 1,499.2440 | 371k | 37M | 9M | -243.5 | -14.55% |
